| Symbol | CCCC |
|---|---|
| Name | C4 THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 490 ARSENAL WAY,SUITE 200, WATERTOWN, Massachusetts, 02472, United States |
| Telephone | +1 617 231-0700 |
| Fax | — |
| — | |
| Website | https://www.c4therapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001662579 |
| Description | C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the bodys natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. Additional info from NASDAQ: |
Director Anderson Kenneth Carl 🟢 acquired 2.6K shares of C4 Therapeutics, Inc. (CCCC) at $4.34 Transaction Date: Jul 01, 2026 | Filing ID: 000688
Read moreDirector GROGAN DONNA ROY 🟢 acquired 3.3K shares of C4 Therapeutics, Inc. (CCCC) at $4.34 Transaction Date: Jul 01, 2026 | Filing ID: 000689
Read moreDirector Hughes Owen 🟢 acquired 62.0K shares (1 derivative) of C4 Therapeutics, Inc. (CCCC) at $4.25 Transaction Date: Jun 24, 2026 | Filing ID: 000673
Read moreDirector Hoerter Steven L. 🟢 acquired 62.0K shares (1 derivative) of C4 Therapeutics, Inc. (CCCC) at $4.25 Transaction Date: Jun 24, 2026 | Filing ID: 000670
Read moreDirector Koppikar Utpal 🟢 acquired 62.0K shares (1 derivative) of C4 Therapeutics, Inc. (CCCC) at $4.25 Transaction Date: Jun 24, 2026 | Filing ID: 000667
Read more(85% Positive) C4 THERAPEUTICS, INC. (CCCC) Announces Enrollment Update for success Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreC4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
Read moreDirector Anderson Kenneth Carl 🟡 adjusted position in 0 shares (1 derivative) of C4 Therapeutics, Inc. (CCCC) at $2.11 Transaction Date: Jun 01, 2026 | Filing ID: 000504
Read more📋 Mark Mossler (Ex-Section 16 Officer) plans to sell 9K shares of C4 Therapeutics, Inc. (at $3.90 each, total $35K) Filed: May 28, 2026 | ID: 245847
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07284758 | A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants… | Phase2 | Multiple Myeloma | Recruiting | 2026-02-18 | 2030-03-01 | ClinicalTrials.gov |
| NCT07280013 | A Study to Learn About the Effects of Cemsidomide in Combination With Elranatam… | Phase1 | Multiple Myeloma (MM) | Recruiting | 2026-02-06 | 2029-06-01 | ClinicalTrials.gov |
| NCT05668585 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of C… | Phase1 | Solid Tumors | Completed | 2022-12-08 | 2025-11-05 | ClinicalTrials.gov |
| NCT05355753 | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or… | Phase1 | Synovial Sarcoma | Terminated | 2022-03-25 | 2023-12-19 | ClinicalTrials.gov |
| NCT04756726 | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory N… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2021-04-27 | 2026-12-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| Cemsidomide | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| CFT8634 | Other | Phase PHASE1 | Synovial Sarcoma | TERMINATED | NCT05355753 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| Cemsidomide | Other | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| Cetuximab | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05668585 |
| Trametinib | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05668585 |
| CFT1946 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05668585 |
| Dexamethasone Oral | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04756726 |
| cemsidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04756726 |
| Elranatamab | Other | Phase PHASE1 | Multiple Myeloma (MM) | RECRUITING | NCT07280013 |
| Cemsidomide | Other | Phase PHASE1 | Multiple Myeloma (MM) | RECRUITING | NCT07280013 |
| Elranatamab | Other | Phase PHASE1 | Multiple Myeloma (MM) | RECRUITING | NCT07280013 |
| Cemsidomide | Other | Phase PHASE1 | Multiple Myeloma (MM) | RECRUITING | NCT07280013 |
| Dexamethasone | DRUG | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| Elranatamab | BIOLOGICAL | Phase PHASE1 | Multiple Myeloma (MM) | RECRUITING | NCT07280013 |
| Cemsidomide | DRUG | Phase PHASE2 | Multiple Myeloma | RECRUITING | NCT07284758 |
| Cetuximab | DRUG | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05668585 |
| Trametinib | DRUG | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05668585 |
| CFT1946 | DRUG | Phase PHASE1 | Solid Tumors | COMPLETED | NCT05668585 |
| CFT8634 | DRUG | Phase PHASE1 | Synovial Sarcoma | TERMINATED | NCT05355753 |
| Dexamethasone Oral | DRUG | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04756726 |
| cemsidomide | DRUG | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04756726 |